Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension
NCT02906579Phase 2Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- Sep 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of praliciguat in type 2 diabetes mellitus (T2DM) and hypertension (HTN), sponsored by Cyclerion Therapeutics. Primary endpoints: Treatment Emergent Adverse Events at Day 46, Clinical Chemistry Laboratory Parameters at Day 32 and 16 more. Started Sep 2016; status: completed.
02
Drugs
praliciguat
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT02906579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906579.